Skip to main content

Advertisement

SpringerLink
Log in

Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Objective

Our objectives were to develop the population pharmacokinetic (PK) for pertuzumab and examine the variability of steady-state trough serum concentrations (C SS,trough) and exposure after fixed, body-weight-based, or body-surface area (BSA)-based dosing methods in cancer patients.

Methods

Pertuzumab was administered by IV infusion (every 3 weeks) either as a weight-based dose (0.5–15 mg/kg) or a fixed dose (420 or 1050 mg). Data from three clinical studies, comprising 153 patients and 1458 concentration-time points, were pooled for this analysis using NONMEM.

Results

A linear two-compartment model best described the data. Body weight and BSA were significant covariates affecting clearance (CL) and distribution volume (Vc), respectively. However, weight and BSA only explained small percentage of interpatient variability for CL and Vc, respectively. Simulation results indicated that PK profiles were very similar after the three dosing methods. Compared to fixed dosing, weight- and BSA-based dosing only reduced the population variability of C SS,trough moderately.

Conclusion

A population PK model was developed for pertuzumab, the first monoclonal IgG1 antibody in a new class of agents known as HER dimerization inhibitors. In addition, our analyses demonstrate the feasibility of administering pertuzumab using a fixed dose in women with ovarian and breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. D. Harari Y. Yarden (2000) ArticleTitleMolecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene 19 6102–6114 Occurrence Handle11156523 Occurrence Handle1:CAS:528:DC%2BD3MXhsFyhtrg%3D Occurrence Handle10.1038/sj.onc.1203973

    Article  PubMed  CAS  Google Scholar 

  2. Y. Yarden M. X. Sliwkowski (2001) ArticleTitleUntangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 127–137 Occurrence Handle11252954 Occurrence Handle1:CAS:528:DC%2BD3MXivVWnt7k%3D Occurrence Handle10.1038/35052073

    Article  PubMed  CAS  Google Scholar 

  3. M. X. Sliwkowski (2003) ArticleTitleReady to partner Nat. Struct. Biol. 10 158–159 Occurrence Handle12605220 Occurrence Handle1:CAS:528:DC%2BD3sXhsVaksb8%3D Occurrence Handle10.1038/nsb0303-158

    Article  PubMed  CAS  Google Scholar 

  4. H. S. Cho K. Mason K. X. Ramyar A. M. Stanley S. B. Gabelli D. W. Denney SuffixJr. D. J. Leahy (2003) ArticleTitleStructure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 756–760 Occurrence Handle12610629 Occurrence Handle1:CAS:528:DC%2BD3sXhsV2rtrw%3D Occurrence Handle10.1038/nature01392

    Article  PubMed  CAS  Google Scholar 

  5. D. B. Agus R. W. Akita W. D. Fox G. D. Lewis B. Higgins P. I. Pisacane J. A. Lofgren C. Tindell D. P. Evans K. Maiese H. I. Scher M. X. Sliwkowski (2002) ArticleTitleTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 127–137 Occurrence Handle12204533 Occurrence Handle1:CAS:528:DC%2BD38XmslSksL4%3D Occurrence Handle10.1016/S1535-6108(02)00097-1

    Article  PubMed  CAS  Google Scholar 

  6. C. L. Arteaga (2003) ArticleTitleErbB-targeted therapeutic approaches in human cancer Exp. Cell Res. 284 122–130 Occurrence Handle12648471 Occurrence Handle1:CAS:528:DC%2BD3sXitVylt7c%3D Occurrence Handle10.1016/S0014-4827(02)00104-0

    Article  PubMed  CAS  Google Scholar 

  7. D. B. Agus M. S. Gordon C. Taylor R. B. Natale B. Karlan D. S. Mendelson M. F. Press D. E. Allison M. X. Sliwkowski G. Lieberman S. M. Kelsey G. Fyfe (2005) ArticleTitlePhase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J. Clin. Oncol. 23 2534–2543 Occurrence Handle15699478 Occurrence Handle1:CAS:528:DC%2BD2MXjvVyktLk%3D Occurrence Handle10.1200/JCO.2005.03.184

    Article  PubMed  CAS  Google Scholar 

  8. D. E. Allison M. A. Malik F. Qureshi D. Baker S. Kelsey G. Fyfe M. Gordon C. Taylor D. B. Agus (2003) ArticleTitlePharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: Phase Ia results Proc. Am. Soc. Clin. Oncol. 22 197

    Google Scholar 

  9. J. F. Lu S. Gourley R. Bruno (2003) ArticleTitleWhen should dose be adjusted to body size? A population pharmacokinetic (PPK) simulation Clin. Pharmacol. Ther. 73 86 Occurrence Handle10.1016/S0009-9236(03)90674-6

    Article  Google Scholar 

  10. M. J. Egorin (2003) ArticleTitleHorseshoes, hand grenades, and body-surface area-based dosing: aiming for a target J. Clin. Oncol. 21 182–183 Occurrence Handle12525507 Occurrence Handle10.1200/JCO.2003.10.084

    Article  PubMed  Google Scholar 

  11. S. D. Baker J. Verweij E. K. Rowinsky R. C. Donehower J. H. Schellens L. B. Grochow A. Sparreboom (2002) ArticleTitleRole of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 J. Natl. Cancer Inst. 94 1883–1888 Occurrence Handle12488482 Occurrence Handle1:CAS:528:DC%2BD3sXlsFyisA%3D%3D

    PubMed  CAS  Google Scholar 

  12. A. Felici J. Verweij A. Sparreboom (2002) ArticleTitleDosing strategies for anticancer drugs: the good, the bad and body-surface area Eur. J. Cancer 38 1677–1684 Occurrence Handle12175683 Occurrence Handle1:CAS:528:DC%2BD38XmtVSmtb4%3D Occurrence Handle10.1016/S0959-8049(02)00151-X

    Article  PubMed  CAS  Google Scholar 

  13. A. J. Boeckmann S. L. Beal (1994) NONMEM User Guide, NONMEM Project Group University of California San Francisco

    Google Scholar 

  14. U. Wahlby E. N. Jonsson M. O. Karlsson (2001) ArticleTitleAssessment of actual significance levels for covariate effects in NONMEM J. Pharmacokinet. Pharmacodyn. 28 231–252 Occurrence Handle11468939 Occurrence Handle1:STN:280:DC%2BD38%2FitlOktA%3D%3D Occurrence Handle10.1023/A:1011527125570

    Article  PubMed  CAS  Google Scholar 

  15. Y. Yano S. L. Beal L. B. Sheiner (2001) ArticleTitleEvaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J. Pharmacokinet. Pharmacodyn. 28 171–192 Occurrence Handle11381569 Occurrence Handle1:STN:280:DC%2BD38%2FhtV2htg%3D%3D Occurrence Handle10.1023/A:1011555016423

    Article  PubMed  CAS  Google Scholar 

  16. A. Gelman X. L. Meng (1996) Model checking and model improvement W. R. Gilks S. Richardson D. J. Spiegelhalter (Eds) Markov Chain Monte Carlo in Practice Chapman & Hall/CRC Boca Raton 189–202

    Google Scholar 

  17. A. Gelman J. B. Carlin H. S. Stern D. B. Rubin (2004) Bayesian Data Analysis Chapman & Hall/CRC Boca Raton

    Google Scholar 

  18. K. A. Harris C. B. Washington G. Lieberman J. F. Lu R. Mass R. Bruno (2002) ArticleTitleA population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing Proc. Am. Soc. Clin. Oncol. 21 488a

    Google Scholar 

  19. B. Leyland-Jones K. Gelmon J. P. Ayoub A. Arnold S. Verma R. Dias P. Ghahramani (2003) ArticleTitlePharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J. Clin. Oncol. 21 3965–3971 Occurrence Handle14507946 Occurrence Handle1:CAS:528:DC%2BD2cXpsVajsb0%3D Occurrence Handle10.1200/JCO.2003.12.109

    Article  PubMed  CAS  Google Scholar 

  20. J. F. Lu J. Gaudreault W. Novotny B. Lum R. Bruno (2004) ArticleTitleA population pharmacokinetic model for bevacizumab Clin. Pharmacol. Ther. 75 91 Occurrence Handle10.1016/j.clpt.2003.11.347

    Article  Google Scholar 

  21. M. A. Malik K. Totpal I. Balter M. X. Sliwkowski N. Pelltier M. Reich T. Crocker S. Freiss S. Bauer N. H. Fiebig D. E. Allison (2003) ArticleTitleDose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models Proc. Am. Soc. Cancer Res. 44 176–177

    Google Scholar 

  22. W. J. Loos H. Gelderblom A. Sparreboom J. Verweij M. J. Jonge Particlede (2000) ArticleTitleInter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens Clin. Cancer Res. 6 2685–2689 Occurrence Handle10914710 Occurrence Handle1:CAS:528:DC%2BD3cXlslent70%3D

    PubMed  CAS  Google Scholar 

  23. F. E. Jongh Particlede J. Verweij W. J. Loos R. Wit Particlede M. J. Jonge Particlede A. S. Planting K. Nooter G. Stoter A. Sparreboom (2001) ArticleTitleBody-surface area-based dosing does not increase accuracy of predicting cisplatin exposure J. Clin. Oncol. 19 3733–3739 Occurrence Handle11533095

    PubMed  Google Scholar 

  24. R. H. Mathijssen J. Verweij M. J. Jonge Particlede K. Nooter G. Stoter A. Sparreboom (2002) ArticleTitleImpact of body-size measures on irinotecan clearance: alternative dosing recommendations J. Clin. Oncol. 20 81–87 Occurrence Handle11773157 Occurrence Handle1:CAS:528:DC%2BD38XnsFersg%3D%3D Occurrence Handle10.1200/JCO.20.1.81

    Article  PubMed  CAS  Google Scholar 

  25. F. A. Jong Particlede R. H. Mathijssen R. Xie J. Verweij A. Sparreboom (2004) ArticleTitleFlat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability Clin. Cancer Res. 10 4068–4071 Occurrence Handle15217940 Occurrence Handle10.1158/1078-0432.CCR-03-0591

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Inc., 1 DNA Way MS70, South San Francisco, California, 94080-4990, USA

    Chee M. Ng, Bert L. Lum & David Allison

  2. Department of Oncology, Hoffman-La Roche, Basel, Switzerland

    Veronica Gimenez

  3. Department of BioOncology, Genentech Inc., South San Francisco, California, 94080-4990, USA

    Steve Kelsey

Authors
  1. Chee M. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bert L. Lum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veronica Gimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steve Kelsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chee M. Ng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ng, C.M., Lum, B.L., Gimenez, V. et al. Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis. Pharm Res 23, 1275–1284 (2006). https://doi.org/10.1007/s11095-006-0205-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-006-0205-x

Key Words

Search

Navigation